Shore Capital Group Reaffirms Buy Rating for Smith & Nephew (LON:SN)

Smith & Nephew (LON:SN)‘s stock had its “buy” rating reissued by Shore Capital Group in a report released on Tuesday,Digital Look reports. They currently have a GBX 1,000 price objective on the stock. Shore Capital Group’s price target would suggest a potential downside of 11.07% from the stock’s current price.

A number of other equities analysts also recently issued reports on the stock. Citigroup downgraded shares of Smith & Nephew to a “buy” rating in a report on Friday, July 10th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,760 target price on shares of Smith & Nephew in a report on Thursday, May 21st. UBS Group reissued a “neutral” rating and set a GBX 1,300 price target on shares of Smith & Nephew in a research report on Tuesday, May 5th. Royal Bank Of Canada restated a “sector perform” rating and set a GBX 1,350 price target on shares of Smith & Nephew in a report on Monday, June 29th. Finally, Berenberg Bank reaffirmed a “hold” rating and issued a GBX 13 price objective on shares of Smith & Nephew in a research report on Friday, May 1st. Four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Smith & Nephew presently has an average rating of “Hold” and an average target price of GBX 1,340.11.

Smith & Nephew Stock Down 1.2%

Shares of LON:SN opened at GBX 1,124.50 on Tuesday. The firm’s 50-day moving average is GBX 1,130.10 and its 200 day moving average is GBX 1,199.51. The stock has a market capitalization of £12.33 billion, a PE ratio of 40.49, a price-to-earnings-growth ratio of 0.46 and a beta of 0.68. The company has a debt-to-equity ratio of 62.90, a quick ratio of 0.84 and a current ratio of 2.57.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.